Cardio Diagnostics
CDIO
Market cap $7.75M

4.46 USD

+0.04

0.90%

At close Jul 15, 4:00 PM EDT

1 day

0.90%

5 days

9.05%

1 month

12.91%

3 months

-62.71%

6 months

-74.80%

Year to date

-82.99%

1 year

-70.62%

5 years

-98.49%

10 years

-98.49%

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Employees: 9

Healthcare Biotechnology

0

Funds holding %

of 7,316 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

0% more funds holding

Funds holding: 23 [Q4 2024] → 23 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

1.49% less ownership

Funds ownership: 6.36% [Q4 2024] → 4.86% (-1.49%) [Q1 2025]

65% less capital invested

Capital invested by funds: $2.36M [Q4 2024] → $836K (-$1.52M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CDIO.

See Analyst Rankings

Financial journalist opinion

Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced an agreement with AGEPHA Pharma.

Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's IP portfolio.

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price.

Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price

Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States.

Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.

Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations.

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced their PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from CMS.

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference.

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS.

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

See News Rankings

Charts implemented using Lightweight Charts™